My Forever Portfolio: 5 Stocks I Don't Plan on Ever Selling

The analyst outlines a five-stock "forever" portfolio—Amazon, Apple, Berkshire Hathaway, Intuitive Surgical and Vertex Pharmaceuticals—highlighting durable competitive advantages and long-term growth catalysts. Key data points: Amazon Web Services generated $93 billion in sales in the first nine months of 2025 and accounted for 59% of Amazon's operating income; Intuitive estimates ~8 million procedures are currently addressable by cleared products, rising to ~22 million including products/clearances in development; Vertex leverages a leading cystic fibrosis franchise and is pursuing pipeline assets including povetacicept for IgA nephropathy (addressable ~330,000 patients in the U.S. and Europe), inaxaplin and zimislecel. The piece emphasizes management continuity at Berkshire under Greg Abel, potential new end markets for Apple (AI glasses, 6G) and positions held by the author and The Motley Fool.

Analysis

Market structure: Megacaps named (AMZN, AAPL, BRK) gain persistent pricing power—AWS (59% of op income, $93bn YTD) and Apple’s ecosystem drive cash generation and optionality (satcom, AI glasses, 6G). Vertex (VRTX) retains monopoly economics in CF and expanding kidney/diabetes TAMs (CF → 330k; IgA nephropathy ~3x CF), while Intuitive (ISRG) benefits from an ageing population and a robotics TAM that management pegs rising from 8M → 22M procedures. Flow effects: concentration in megacaps will likely depress single-stock implied vols and tighten IG spreads modestly; semiconductor/AI demand supports copper/industrial metal real assets over 6–24 months.

Risk assessment: Key tail risks are regulatory antitrust for AMZN/AAPL and binary clinical/FDA failures for VRTX (single trial failure can cut value >40%). Execution risks: AWS pricing or capital intensity of Amazon satellite/robotics could push free cash flow volatility +/-15% year-over-year. Time horizons: earnings/FY guidance move in days–weeks, FDA readouts and product launches in 3–18 months, structural moat outcomes 3–7 years. Hidden dependencies include Amazon’s spectrum/capex build for satcom and Vertex’s manufacturing scale for gene therapies.

Trade implications: Tactical longs in AMZN (2–3% weight) and AAPL (3–4%) for 12–36 months, scaling on 7–10% pullbacks; hedge biotech binary risk via long-dated VRTX call spreads (12–24 months) sized 0.5–1% not outright calls. Relative-value: pair long ISRG (1.5–2%) vs short ZBH (1.5%) to capture robotic share shifts over 12 months. Options: sell short-dated premium into earnings for megacaps; buy 6–12 month OTM call spreads on AMZN/AAPL around product cadence.

Contrarian angles: Consensus underprices regulatory and clinical downside—assign 20–30% probability to significant antitrust action versus tech mega-caps and 30–50% to single-drug clinical failure for early Vertex targets, implying current VRTX pricing already bakes success. BRK.B is an under-owned defensive play if volatility re-prices equities (consider 1–2% allocation on S&P drop >8% or VIX >22). Unintended consequences: heavy concentration increases liquidity risk in a drawdown; Amazon robotics/satcom may be capital intensive and delay value realization beyond 24 months.

Key Decisions for Investors

• Establish a 2–3% long position in AMZN for a 12–24 month horizon; scale in on any 7–10% pullback. Target +30% upside or trim to half position if FCF growth falls >15% QoQ; stop-loss at -18%.
• Establish a 3–4% long position in AAPL, buy into dips >5% and hold 12–36 months for device/services optionality. Trim to 50% if iPhone revenue growth slips below 0% YoY for two consecutive quarters.
• Initiate a paired trade: long ISRG 1.5–2% vs short ZBH 1.5% (equal notional) to capture robotic surgery share shift over 12 months; review after major FDA/regulatory announcements or if ISRG net-new procedure adoption <+15% YoY.
• Use options to manage biotech binary risk: buy a 12–24 month VRTX call spread sized 0.5–1% (buy farther-dated call, sell nearer-term call) only if a PDUFA/Phase-3 readout for povetacicept or inaxaplin is scheduled within 6–18 months. If FDA calendar shows no near-term catalysts, cap exposure at 0.5%.
• Add 1–2% BRK.B as a tactical defensive allocation if S&P 500 declines >8% or VIX >22; otherwise keep BRK exposure <=1% for diversification. Monitor Berkshire’s buyback cadence and CEO commentary quarterly before increasing allocation.